Lumos Pharma, Inc.
LUMO · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $2,051 | $1,523 | $230 | $168 |
| % Growth | 34.7% | 562.2% | 36.9% | – |
| Cost of Goods Sold | $0 | $49 | $0 | $0 |
| Gross Profit | $2,051 | $1,474 | $230 | $168 |
| % Margin | 100% | 96.8% | 100% | 100% |
| R&D Expenses | $22,096 | $17,857 | $16,246 | $9,206 |
| G&A Expenses | $16,569 | $15,706 | $15,331 | $17,265 |
| SG&A Expenses | $16,569 | $15,706 | $15,331 | $17,265 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $91 | $269 | $0 |
| Operating Expenses | $38,665 | $33,563 | $31,577 | $26,471 |
| Operating Income | -$36,614 | -$32,040 | -$31,347 | -$26,303 |
| % Margin | -1,785.2% | -2,103.7% | -13,629.1% | -15,656.5% |
| Other Income/Exp. Net | $2,551 | $965 | $281 | $6,667 |
| Pre-Tax Income | -$34,063 | -$31,075 | -$31,066 | -$19,636 |
| Tax Expense | -$29 | -$13 | -$636 | -$13,973 |
| Net Income | -$34,034 | -$31,062 | -$30,430 | -$5,663 |
| % Margin | -1,659.4% | -2,039.5% | -13,230.4% | -3,370.8% |
| EPS | -4.18 | -3.71 | -3.65 | -0.84 |
| % Growth | -12.7% | -1.6% | -334.5% | – |
| EPS Diluted | -4.18 | -3.71 | -3.65 | -0.84 |
| Weighted Avg Shares Out | 8,145 | 8,374 | 8,335 | 6,778 |
| Weighted Avg Shares Out Dil | 8,145 | 8,374 | 8,335 | 6,778 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,868 | $874 | $12 | $200 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $44 | $49 | $273 | $584 |
| EBITDA | -$36,570 | -$31,991 | -$31,130 | -$25,719 |
| % Margin | -1,783% | -2,100.5% | -13,534.8% | -15,308.9% |